Atreca (BCEL)
(Delayed Data from OTC)
$0.09 USD
0.00 (4.65%)
Updated Jun 7, 2024 03:40 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Atreca, Inc. [BCEL]
Reports for Purchase
Showing records 101 - 120 ( 159 total )
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Atreca Targets Under Stress: Initial Data Mid-Year
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Glass Half Full: Our Top Biotech & Healthcare Ideas for 2021
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; Driving Toward ATRC-101 First Clinical Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 - Trial Sites Expanded. Initial Data in 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Notable Events/Catalysts from Our Coverage Universe for the Remainder of 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Ph 1b Continues Enrollment; Updated Expansion Study Plans
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Driving Towards Initial ATRC-101 Data; PT Tweaked to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Xencor Deal Highlights Platform Value; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Atreca Utilizing Its Unique Platform with Xencor Collaboration
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Strong Rationale and Data for Atreca''s Unique Antibody Against Cancer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
ATRC-101 MoA Garners Significant Scientific Support
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J